ArticleJournal of thoracic disease2026
Assessment of susceptibility to mTOR rs2295080 gene polymorphism in Guangxi Zhuang lung cancer population.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a leading cause of cancer-related deaths globally. While single-nucleotide polymorphisms (SNPs) are established genetic modulators of cancer susceptibility, the specific functions of SNPs in the mammalian target of rapamycin (mTOR) pathway in lung cancer pathogenesis remain largely unclear. This study investigated the associations between a specific SNP in the promoter region of the mTOR gene, the corresponding mTOR protein expression levels, and lung cancer susceptibility in the study population. Methods: Genotyping of 136 healthy controls and 241 lung cancer patients was performed using SNP scanning high-throughput technology. Lung cancer patients were further classified into lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and small cell lung cancer (SCLC). Logistic regression, independent samples Results: The results showed that mTOR-rs2295080 was significantly associated with the risk of developing LUAD and SCLC. The GT genotype reduced the risk of LUAD compared with the TT genotype [odds ratio (OR) =0.513; 95% confidence interval (CI): 0.300-0.877; P=0.02]. The G allele reduced the risk of SCLC compared to the T allele (OR =0.377; 95% CI: 0.185-0.769; P=0.007). IHC results according to genotype and pathology type showed that rs2295080-GT had the lowest protein expression levels of MTOR in tumor tissues of LUAD and LUSC patients compared to those of GG and TT. Conclusions: The mTOR rs2295080 polymorphism is associated with a reduced risk of lung cancer and may exert a protective effect by reducing protein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.